Dr. Flammer Martina, Chief Medical Officer of Insmed Incorporated (INSM), has been a consistent seller of company stock over the past year, with SEC Form 4 filings showing 67 total transactions—all of them sales or mechanically linked option exercises. The data reveals a pronounced sell-side bias: total sales value reached $47.7 million, while open-market purchases totaled zero. The most recent cluster of activity, spanning January through July 2026, shows 21 separate sell transactions, with individual sales ranging from roughly $15,700 to $1.23 million. Notable large disposals occurred on May 11, 2026 ($1.22 million), May 14, 2026 ($1.23 million), and July 6, 2026 ($823,748 and $529,183), the latter paired with option exercises valued at $86,007 and $231,438.
The pattern is consistent with routine portfolio management by a senior executive: sales are frequently paired with option exercises (coded "M" in the filings), which are mechanical conversions of previously granted equity rather than discretionary purchases. For instance, on February 2, 2026, Flammer exercised options worth $524,577 while simultaneously selling shares in five separate transactions totaling approximately $1.24 million. Similarly, the July 6, 2026 filings show option exercises of $317,445 combined with sales of $1.35 million. This recurring structure—exercise and immediate sell—suggests a systematic approach to monetizing vested equity awards rather than a reaction to company-specific developments.
Across the entire filing history, there are no open-market purchases (code "P") and no acquisitions (code "A" or "C") that would indicate fresh capital commitment. The sell-only pattern, concentrated entirely in INSM, reflects a clear directional bias: Flammer has been a net liquidator of her position throughout the period, with the most recent trades continuing that trend into July 2026. While the filings do not disclose her remaining holdings, the consistent monthly cadence of sales—often clustered at the start of each month—points to a pre-arranged selling schedule rather than opportunistic timing.
AI-assisted summary